Dementia (Dementias)

Subscribe to Selected New Research on Dementia

11649 relevant articles (595 outcomes, 1856 trials/studies) found for this Disease

Description: An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.

Also Known As:

Dementias; Frontotemporal Lobar Degeneration; Semantic Dementia; Dementia, Familial; Degeneration, Frontotemporal Lobar; Dementia, Semantic; Amentia; Familial Dementia; Amentias; Degenerations, Frontotemporal Lobar; Dementias, Familial; Dementias, Semantic; Dementias, Senile Paranoid; Familial Dementias; Frontotemporal Lobar Degenerations; Lobar Degeneration, Frontotemporal; Lobar Degenerations, Frontotemporal; Paranoid Dementia, Senile; Paranoid Dementias, Senile; Semantic Dementias; Senile Paranoid Dementias; Senile Paranoid Dementia

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Alzheimer Disease (Alzheimer's Disease)
2.	Parkinson Disease (Parkinson's Disease)
3.	Syndrome
4.	Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy)
5.	Schizophrenia (Dementia Praecox)

Experts

1.	Lee, Virginia M-Y: 17 articles (07/2008 - 05/2002)
2.	Trojanowski, John Q: 17 articles (07/2008 - 05/2002)
3.	Zimmerman, Sheryl: 16 articles (02/2008 - 09/2003)
4.	Mitchell, Susan L: 15 articles (08/2008 - 01/2003)
5.	McKeith, Ian G: 14 articles (11/2007 - 01/2002)
6.	Neumann, Manuela: 13 articles (07/2008 - 01/2005)
7.	Ribbe, Miel W: 13 articles (10/2007 - 03/2002)
8.	Launer, Lenore J: 12 articles (08/2008 - 04/2002)
9.	McKeith, I G: 12 articles (04/2008 - 01/2000)
10.	Breteler, Monique M B: 11 articles (06/2008 - 05/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Dementia:

1.	Cholinesterase Inhibitors (Anticholinesterases)IBA 01/01/2004 - "Observations on the neurochemistry of dementia with Lewy bodies (DLB) have suggested that cholinesterase inhibitors (ChEIs) might be beneficial in treating some clinical symptoms of DLB. " 04/01/2005 - "Recent evidence from small double-blind and open-label trials suggests that cholinesterase inhibitors may be effective in the treatment of dementia associated with PD." 08/01/2004 - "Several small studies with three different cholinesterase inhibitors suggest that these drugs can be effective in the treatment of PD dementia. " 04/01/2003 - "Recent evidence from small studies suggests that cholinesterase inhibitors may be effective in the treatment of dementia associated with PD." 06/01/2009 - "CONCLUSIONS: This case confirms the idea that treatment with cholinesterase inhibitors can be effective in the behavioural and psychological symptoms of frontotemporal dementia." Order ALL the reference details at left...
2.	Memantine (Namenda)FDA Link 03/01/2004 - "In randomized, controlled studies it has been shown that memantine is beneficial in the treatment of moderate to severe dementia of Alzheimer's type and it became the very first compound to be registered for this purpose both in Europe (including Poland) and in the United States. " 01/20/2010 - "We hypothesized that memantine, an anti-dementia drug, may be useful for the treatment of excessive daytime sleepiness. " 06/01/2000 - "The efficacy of memantine in a variety of dementias has been shown in clinical trials. " 11/01/2008 - "The effect of 12-week open-label memantine treatment on cognitive function improvement in patients with alcohol-related dementia." 01/01/2008 - "Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis." Order ALL the reference details at left...
3.	Risperidone (Risperdal Consta)FDA LinkGeneric 10/09/2003 - "CONCLUSION: Risperidone was highly effective and well tolerated in the treatment of behavioural disturbances in dementia under routine conditions of general practice." 03/01/2005 - "CONCLUSIONS: In this study of community-based patients with dementia, risperidone significantly improved behavioral and psychological symptoms and, as a result, also reduced caregiver burden. " 02/01/2003 - "CONCLUSION: Treatment with low-dose (mean = 0.95 mg/day) risperidone resulted in significant improvement in aggression, agitation, and psychosis associated with dementia." 02/01/1999 - "CONCLUSION: Risperidone significantly improved symptoms of psychosis and aggressive behavior in patients with severe dementia. " 01/01/2001 - "Numerous open-label and, more recently, placebo-controlled trials have documented the efficacy of risperidone in the management of behavioral and psychological symptoms of dementia. " Order ALL the reference details at left...
4.	donepezil (Aricept)FDA LinkGeneric 01/01/2006 - "Treatment with donepezil was only effective in PD patients with dementia, who experience nearly no side effects from the drug." 01/01/2006 - "Objectives of this investigator initiated multicenter open label trial were to confirm the efficacy of donepezil in the treatment of dementia in PD patients and to investigate the tolerability and safety of donepezil. " 03/01/2004 - "He was treated with donepezil for alcohol-related dementia, and 3 months later, his cognitive function had improved. " 12/01/2001 - "CONCLUSION: Patients treated with donepezil maintained or improved in cognition and overall dementia severity in contrast to placebo-treated patients who declined during the 6-month treatment period. " 01/01/2009 - "The aim of this trial is to establish the most effective drug option for people with AD who are progressing from moderate to severe dementia despite treatment with donepezil. " Order ALL the reference details at left...
5.	Antipsychotic Agents (Antipsychotics)IBA 04/01/2008 - "BACKGROUND: There have been increasing concerns regarding the safety and efficacy of neuroleptics in people with dementia, but there are very few long-term trials to inform clinical practice. " 05/01/2000 - "Traditional neuroleptics have been the mainstay of treatment for agitated behavior in persons with dementia, but these agents have limited efficacy and are associated with high rates of adverse effects, including worsening of already poor cognitive functioning. " 04/01/2008 - "Thus, there is insufficient evidence to suggest that psychotropics other than antipsychotics represent an overall effective and safe, let alone better, treatment choice for psychosis or agitation in dementia; currently no such treatment has been approved by the FDA for these symptoms. " 05/01/1990 - "Prior qualitative literature reviews about the use of neuroleptics in dementia suggest that they are "modestly effective" in treating agitation and that no single neuroleptic is better than another. " 01/01/2008 - "Numerous recent studies have challenged the widely held belief that atypical antipsychotics are safe and effective options for the treatment of behavioural problems such as agitation in patients with dementia. " Order ALL the reference details at left...
6.	rivastigmine (Exelon)FDA LinkGeneric 09/01/2006 - "The aim of the present study (a double-blind, placebo-controlled clinical trial) was to determine the utility of the Mattis dementia rating scale - the most commonly used scale in PD patients - to assess the efficacy of a 24-week rivastigmine treatment. " 06/01/2009 - "Their effectiveness in frontotemporal dementia has not been proved, since such a claim has only been backed by the publication of one open-label trial in which the behavioural and psychological symptoms of the patients treated with rivastigmine over a 12-month period improved significantly with respect to those belonging to a group that were given a placebo. " 09/01/2006 - "RESULTS: Compared with placebo, a 24-week rivastigmine treatment led to a significant improvement in the overall score on the Mattis dementia rating scale (p = 0.031), with a trend towards a significant improvement in the "Attention" subscale score (p = 0.061). " 01/01/2003 - "Preliminary data suggest that rivastigmine may provide significant benefits in patients with AD and cerebrovascular disease (mixed dementia), and in patients with VaD. " 12/16/2000 - "Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study." Order ALL the reference details at left...
7.	Estrogens (Estrogen)FDA Link 07/01/2002 - "RESULTS: Estrogen therapy was associated with a significantly greater improvement on the Dementia Signs and Symptoms Scale total score than placebo. " 06/01/2005 - "Taking into account the results of the WHIMS and the adverse health events associated with the use of estrogen plus progestin or estrogen alone, we conclude that HRT cannot be recommended as a safe and effective strategy to prevent dementia." 08/01/1994 - "This study was designed to investigate the therapeutic efficacy of estrogen in female patients with dementia of the Alzheimer type (DAT). " 03/01/1995 - "Therapeutic efficacy of estrogen was evaluated by psychometric assessments such as the Mini-Mental State Examination (MMSE) and the Hasegawa Dementia Scale (HDS) and a behavior rating scale of the Gottfries-Bråne-Steen geriatric rating scale (GBS). " 06/01/2005 - "Although there is circumstantial support for the role of estrogen, the unexpected results of the Women's Health Initiative (WHI) Memory Study, which reported an increase in the risk for probable dementia and impaired cognitive performance in postmenopausal women treated with a combination of estrogen and progestin, have raised serious questions regarding the protective effects of estrogen. " Order ALL the reference details at left...
8.	Ginkgo biloba extract 761 (Rokan)IBA 01/01/1995 - "Recent studies in which EGb 761 demonstrated therapeutic effects in the treatment of dementia have earned EGb the approval of the German BGA (Bundesgesundheit Amt) for use in the treatment of dementia." 01/01/2007 - "This trial was undertaken to assess the efficacy of EGb 761 in mild to moderate dementia with neuropsychiatric features. " 06/01/2003 - "Taking together, there is experimental evidence for a neuroprotective effect of EGb 761 that agrees with clinical studies showing the efficacy of an oral treatment in patients with mild and moderate dementia." 01/01/2006 - "Probable efficacy of long-term tanakan treatment in prevention of dementia is discussed." 11/01/1997 - "Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type." Order ALL the reference details at left...
9.	Amyloid (Amyloid Fibrils)IBA 09/01/2009 - "Amyloid imaging also shows significant promise in the differential diagnosis of mild cognitive impairment or atypical dementias. " 11/01/2006 - "Novel potential disease-modifying therapies now in preclinical research or clinical trials may be more effective in preventing or arresting the progressive dementia of AD and will provide a test of the amyloid hypothesis." 01/01/2006 - "Therefore, in addition to symptomatic treatment of dementia, therapeutic efforts are currently aimed at testing the efficacy of disease-modifying, anti-amyloid therapies. " 09/15/2009 - "Association of plasma amyloid beta with risk of dementia: the prospective Three-City Study." 01/01/2009 - "Amyloid imaging studies support a model in which amyloid deposition is an early event on the path to dementia, beginning insidiously in cognitively normal individuals, and accompanied by subtle cognitive decline and functional and structural brain changes suggestive of incipient AD. " Order ALL the reference details at left...
10.	Haloperidol (Haldol)FDA LinkGeneric 01/01/2001 - "Except for a favorable response of aggression to haloperidol, no other manifestations of agitated dementia were found to have improved following therapy with haloperidol, compared with controls." 02/01/2002 - "Sixty-two Chinese inpatients with dementia and disruptive behaviors were recruited into an 8-week screening trial of haloperidol. " 01/01/2002 - "4. The present study confirmed that haloperidol should not be used routinely to treat patients with agitated dementia. " 01/01/2002 - "SEARCH STRATEGY: The CDCIG Specialized Register which contains references from medical databases (MEDLINE, EMBASE, PsycInfo and CINAHL) as well as from many trials databases was searched on 26 July 2000 to identify reports of randomised controlled trials on haloperidol treatment of agitation in dementia. " 10/01/2009 - "Haloperidol has long been used to manage agitation in dementia, but it is associated with increased side effects. " Order ALL the reference details at left...

Therapies and Procedures

1.	Home Nursing (Nursing, Home) 12/01/2005 - "RESULTS: Residents who died during the 2-year study period had significantly greater mean rates of utilization of all types of health care than residents who were not discharged from the nursing home, even when controlling for dementia diagnosis, age, functional status, and number of comorbid conditions. " 12/01/2002 - "The purpose of this article is to describe how the use of quantitative (quasi-experimental) and qualitative (grounded-theory) methods in an evaluation of new dementia special care units led to a better understanding of how the nursing home environment affects residents with dementia, which in turn helped to advance theory development in person-environment interaction. " 07/01/1994 - "Although the impact of OBRA 87 on the quality of life of residents with dementia is unknown, the federal regulations constitute a major step in the movement for nursing home reform and toward improved quality of care." 12/01/1992 - "A consultation-liaison psychiatry program in a teaching nursing home helped implement six guiding principles including: make the patient human to the staff; assume no behavior is random; look for depression of psychosis as a source of problems; reduce medications and medication doses; create a more homelike environment; and use conditions in which learning still occurs in dementia." 05/01/2005 - "CONCLUSIONS: Bright light exposure was effective in reducing daytime sleep in nursing home patients with dementia; this finding is possibly related to bright light's acute alerting effects." Order ALL the reference details at left...
2.	Activities of Daily Living (ADL) 12/01/2007 - "Additionally, dementia patients in longterm care (LTC) facilities are prone to significantly greater risk of negative outcomes compared with nondemented residents as a result of a decline in activities of daily living, physical capacities, and behavioral manifestations. " 01/01/1990 - "There was significant improvement of ADL in the patients showing a score of more than 10 on Hasegawa's dementia rating scale and in the patients given drugs to improve cerebral circulation and metabolism, but there was no significant improvement of Hasegawa's dementia rating scale. " 10/01/2005 - "CONCLUSION: Compared with the gymnastics and walking program, the folk play program proved to be much more effective in the elderly with dementia in improving their cognition and ADL, as well as in diminishing their problematic behaviors. " 01/01/2008 - "This study examines the efficacy of a computerized device intended to assist people with dementia through ADL, while reducing caregiver burden. " 01/01/2009 - "BACKGROUND: Instrumental Activities of Daily Living (IADL) questionnaires can be helpful in diagnosing dementia and are often used for clinical follow-up and treatment evaluation in dementia patients. " Order ALL the reference details at left...
3.	Enteral Nutrition (Feeding, Tube) 05/01/2009 - "OBJECTIVES: Despite the evidence that feeding-tube use in persons with advanced dementia is not associated with improved outcomes, there remains striking variation in their use. " 01/01/2009 - "AUTHORS' CONCLUSIONS: Despite the very large number of patients receiving this intervention, there is insufficient evidence to suggest that enteral tube feeding is beneficial in patients with advanced dementia. " 08/01/2009 - "CONCLUSIONS: There is insufficient evidence to suggest that enteral tube feeding is beneficial in people with advanced dementia. " 02/01/2007 - "Knowledge related to the lack of the effect of tube feeding on survival in NH residents with end-stage dementia was the only knowledge item that improved significantly with the intervention (39% correct pre-intervention and 68% correct post-intervention, P = .04). " 01/01/2006 - "Discrepancies between physician knowledge and current evidence regarding tube feeding in advanced dementia were found, indicating a need for improved education ofprimary care physicians in order to ultimately provide better end-of-life care for patients with advanced dementia." Order ALL the reference details at left...
4.	Aftercare (After-Treatment) 01/01/1991 - "The improvement in intellectual function was evaluated by the dementia rating scale for the elderly (DRSE), and a significant increase was found in DRSE after treatment with this drug. " 06/01/2000 - "Fifteen patients who showed mild to moderate dementia improved clinically, and also showed a concomitant increase in their general CBF after treatment. " 01/01/1996 - "However, women with dementia who received either pet therapy or exercise intervention had improved irritable behavior scores after treatment. " 02/01/1988 - "Two cases of mixed depression and dementia showed behavioural and mood improvement after treatment with ECT, but without improvement in cognition. " 02/01/2004 - "However, in the Women's Health Initiative Memory Study - a randomised, placebo-controlled trial of women 65 - 79 years of age - oral oestrogen plus progestin doubled the rate of dementia, with heightened risk appearing soon after treatment was initiated. " Order ALL the reference details at left...
5.	Drug Therapy (Chemotherapy) 01/01/2003 - "There is empirical evidence for the efficacy of pharmacotherapy and more limited evidence for psychosocial interventions in the successful management of aggression in persons with dementia. " 09/15/1991 - "Effective treatment of patients with dementia involves supporting and educating the primary caregiver, uncovering and correcting the underlying cause of any decompensation that may occur, and deciding when drug therapy is appropriate. " 09/01/2001 - "They presented a positive attitude towards managing patients with dementia and considered that existing drug therapy justified an active search for patients with dementia in primary care, but they believed the efficacy of the drugs to be limited. " 04/01/1997 - "Dementia improvement with cytotoxic chemotherapy. " 12/01/1981 - "When no specific treatments are available, however, symptomatic treatments, including pharmacotherapy, environmental management, family supports and psychotherapy, can offer relief for both patients and their families and improve the daily functioning of the elderly patient with dementia." Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Dementia

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 595 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>